SAN CARLOS, CA -- (Marketwired) -- 05/30/17 -- Lion Biotechnologies, Inc.(NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that President and Chief Executive Officer, Dr. Maria Fardis will present an overview of Lion's recent progress and 2017 plans at the upcoming Jefferies 2017 Healthcare Conference on Tuesday, June 6, 2017 at 8:30 a.m. E.T. in New York, NY.
A live webcast of the presentation will be available by visiting the Investors section of Lion Biotechnologies' website at http://ir.lbio.com/. A replay of the webcast will be archived on Lion Biotechnologies' website for 30 days following the presentation.
About Lion Biotechnologies, Inc.
Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with refractory metastatic melanoma, metastatic squamous cell carcinoma of the head and neck, and metastatic cervical carcinoma. For more information, please visit http://www.lionbio.com.
Investor Relations Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah@sternir.com
Media Relations Contact:
Evan Smith/Kotaro Yoshida
FTI Consulting
212-850-5622/212-850-5690
evan.smith@fticonsulting.com
kotaro.yoshida@fticonsulting.com
Source: Lion Biotechnologies, Inc.
